Panel of micrornas as biomarkers of non-segmental vitiligo
A panel of microRNAs serves as biomarkers for non-segmental vitiligo, enabling objective diagnosis and prognosis, and predicting treatment responses, addressing the limitations of existing methods by providing a quantitative assessment of disease severity and progression.
Patent Information
- Application Number
- PCT/ES2024/070299
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-17
- Filing Date
- 2024-05-17
- Publication Date
- 2024-11-21
AI Technical Summary
Current methods for diagnosing and predicting the progression of non-segmental vitiligo lack objective, quantitative, and reliable tools, making it difficult to assess disease severity, progression, and response to treatment, and there is a need for early intervention strategies.
A panel of 6 differentially expressed microRNAs (miRNAs) - miR-16-5p, miR-92a-3p, miR-486-5p, miR-221-3p, miR-23a-3p, and miR-652-3p - are identified as biomarkers in both injured skin and peripheral blood, which can be used to create a predictive model for disease diagnosis and prognosis, and to monitor therapeutic response.
This approach provides an objective and reproducible method for assessing non-segmental vitiligo severity and treatment response, allowing for personalized treatment strategies and the identification of drugs capable of reversing disease dysregulation.
Smart Images

Figure IMGF000010_0001 
Figure IMGF000022_0001
Abstract
Description
[0001] PANEL OF MICRORNAS AS BIOMARKERS OF NON-SEGMENTAL VITILIGO
[0002] DESCRIPTION
[0003] TECHNICAL FIELD
[0004] The present invention falls within the field of medicine, specifically the field of medical prognosis and diagnosis, and even more specifically refers to the use of microRNAs (miRNAs) for the diagnosis and prognosis of non-segmental vitiligo.
[0005] BACKGROUND OF THE INVENTION
[0006] Vitiligo is an autoimmune skin disease characterized by the development of hypopigmented or achromic macules. These macules can present in different distributions on the skin, allowing vitiligo to be classified into two main subtypes: segmental vitiligo, which affects unilateral segments relative to the midline of the body, and non-segmental vitiligo, characterized by the presence of these macules mainly around orifices, on the extremities, and on bony prominences, areas where there is a greater risk of skin trauma.
[0007] Non-segmental vitiligo occurs equally frequently in individuals regardless of race or sex and can develop at any age, although it is most common in the first two decades of life, manifesting before the age of 20 in 50% of cases. The etiology of the disease is unknown, and the biological mechanisms associated with its development include selective apoptosis of melanocytes due to a chronic inflammatory state of the skin involving cytotoxic T cells, natural killer cells, Th1, Th2, Th17 lymphocytes, and IL-23-producing Langerhans cells, as well as metabolic pathways such as WNT and JAK / STAT.
[0008] Disease progression is unpredictable and is characterized by periods of disease inactivity interspersed with slow or rapid depigmentation, which often indicates a worse prognosis and a longer treatment course. To date, there are no methods to predict the progression to these more aggressive forms of non-segmental vitiligo.
[0009] Several drugs targeting severe cases are currently in clinical trials (1), so it would be interesting to know which patients are at higher risk of progressing to more severe forms of the disease and, in these cases, assess whether early therapies would be able to prevent this progression. The criteria for defining disease activity are mainly based on studies conducted with small groups of patients, with the limitations that this implies. The different scales used to estimate the severity of non-segmental vitiligo are based on the calculation of the affected body surface area. To date, several scales have been used, including:
[0010] The Vitiligo Area Scoring Index (VASI) uses a formula that includes the entire body (with a possible range of 0 to 100), which is divided into six separate and mutually exclusive areas (head and neck, hands, upper extremities excluding hands, trunk, lower extremities excluding feet and toes). The percentage of vitiligo involvement in each area is indicated in the form of "hand units" and the degree of depigmentation within these affected hand units. The measurement is performed by clinical personnel.
[0011] - Self Assessed Vitiligo Area Scoring Index (SAVASI) uses the same basic principles as the VASI, adapted for use by the patient, including an illustrated document with a descriptive atlas of patient photographs.
[0012] - The Vitiligo Noticeability Scale (VNS) assesses the patient's visibility of vitiligo lesions after therapy, based on pre- and post-treatment imaging samples, not on changes in their own vitiligo with therapy. There is no evidence to support the reliability of this instrument.
[0013] - The Vitiligo European Task Force Assessment (VETFa) divides the body into five areas (head / neck, hands and feet, trunk, arms, legs) and assesses the extent or percentage of vitiligo involvement using Wallace's rule of nines. It also provides a classification based on the severity of skin and hair depigmentation (stage 0: normal pigmentation; stage 1: incomplete pigmentation; stage 2: complete depigmentation; stage 3: partial hair whitening), giving higher scores when hair is affected. It also assesses disease progression by detecting early stages of depigmentation using a Wood's lamp. However, VETFa only measures one lesion from each body region, missing data on the entire affected BSA.
[0014] The Vitiligo Extent Score (VES) was developed to simplify scales such as VASI and VETFa. It uses a panel of standard images with varying degrees of involvement on different parts of the body as a reference. Clinical staff select those that best represent the patient's skin lesions and then calculate the percentage of depigmented area. The Self-Assessment Vitiligo Extent Score (SA-VES) is a simplified version of the VES tool for use by patients.
[0015] These tools use measurement methods that are not without limitations. The VETFa tool uses Wallace's rule of nines to estimate the extent of affected areas, which assigns each body part divided into eight zones a percentage of multiples of 9, totaling 100%. This method has significant limitations when applied to obese individuals. VASI and SAVASI use "hand units," which depend on the clinical staff's ability to mentally add up all the spots to obtain the equivalent number of palms. VES and SA-VES use templates to assess the extent of vitiligo, with the difficulty of mentally comparing the template with the extent of the disease in patients.
[0016] Furthermore, all of these measurement tools require photographs to assess the disease and are severely limited in their ability to perform measurements when the affected areas are small.
[0017] Attempts have been made to assess the progression of this disease; however, only a qualitative assessment of the speed of development has been achieved, comparing the number of days in which lesions increase in small groups of patients compared to others. To date, no standardized quantitative measure has been identified.
[0018] Other scales allow for the assessment of other processes related to the disease, such as:
[0019] - Koebner's Phenomenon in Vitiligo Score (K-VSCOR), a diagnostic test and mathematical model used to identify patients with a high probability of developing the Koebner phenomenon. The Koebner phenomenon refers to the fact that vitiligo-like lesions can appear on healthy skin when lesions develop thereon.
[0020] - Potential Repigmentation Index (PRI) measures the individual capacity of each lesion to repigment and takes into account the total number of lesions. It classifies lesions into four clinical types of vitiligo: A, B, C, and D, which presumably correspond to the remaining follicular and epidermal reservoirs of melanocytes and precursors.
[0021] - Vitiligo Signs of Activity Score (VSAS) assesses the degree of vitiligo activity by evaluating the number of sites with at least one sign of disease activity. - Vitiligo Disease Activity (VIDA) is a 6-point scale for assessing disease activity and is intended to help evaluate the effectiveness of interventions in halting and reversing the degree of depigmentation. The score is based on the individual's own perception of current disease activity over time. Active vitiligo involves the expansion of existing lesions or the appearance of new lesions. Grading is as follows: VIDA score +4 - Activity lasting 6 weeks or less; +3 - Activity lasting 6 weeks to 3 months; +2 - Activity lasting 3 to 6 months; +1 - Activity lasting 6 to 12 months; 0 - Stable for 1 year or more; and -1 - Stable with spontaneous repigmentation lasting 1 year or more. A lower VIDA score indicates less activity.
[0022] In summary, the most efficient instrument for measuring non-segmental vitiligo is currently VES, including SA-VES, and it has several limitations, including poorer performance in patients with severe disease. Disease severity can be measured with the VASI tool because it combines the extent and degree of depigmentation. However, there is no evidence to recommend the use of SAVASI, considering concerns about its sensitivity. VETFa does not improve VES nor is it able to assess disease progression or stage, while VNS and K-VSCOR lack evidence of reliability.
[0023] None of these scales provide a validated, objective, quantitative tool for jointly and unequivocally assessing the degree of disease progression, the speed of dissemination, and the degree of response to treatment or reversal of depigmentation. Therefore, it is necessary to identify new markers based on large-scale prospective studies with long-term follow-up that will allow for the design of early intervention strategies.
[0024] Other processes related to non-segmental vitiligo have been described as clinical markers, such as the Koebner phenomenon, trichrome lesions, and confetti depigmentation disease. The latter is characterized by lesions measuring one to three millimeters, which can be found in vitiligo, but are more characteristic of chemical leukodermas (skin discolorations) or tuberous sclerosis. Its presence is associated with an unfavorable prognosis, with a higher risk of disease progression and a poor therapeutic response (2).
[0025] A group of proteins related to skin pigmentation processes that belong to the WNT signaling pathway described in patent W02016097035A1 have also been proposed as biomarkers: LEF (Lymphoid enhancer-binding factor), TCF (DNA-binding transcription factor), MITF (Microphthalmia-associated transcription factor), DCT (Dopachrome tautomerase or dopachrome delta-isomerase, tyrosine-related protein 2), PAX3 (transcription factor 3 of the paired box (PAX) family) and the BRn2 transcription factor. They are related to diagnostic and treatment methods for pigmentation disorders, which include vitiligo.
[0026] On the other hand, it is known that a wide variety of miRNAs are associated with genetic polymorphisms (e.g., m¡R-196a-2 rs11614913), immune response (e.g., m¡R-133b, miR-224- 3p, m¡R-4712-3p, m¡R-3940-5p, m¡R -21— 5p), oxidative stress (e.g., m¡R-135a, m¡R- 9, m¡R-34a, m¡R-183, m¡R-184, m¡R-1 , m¡R-25, m¡R-211 , m¡R-383, m¡R-577 , m¡R-421) and melanocyte functions (e.g., m¡R-434-5p, miR-330-5p, miR-137, miR-148, miR-145, miR-155, miR-203, miR-125, miR-377, miR-2909, miR-200c, hsa-miR-149-5p) that participate in the pathological mechanism of vitiligo.
[0027] miRNAs are small, endogenous, non-coding RNAs, approximately 18–25 nucleotides in length, capable of modulating the expression of complementary messenger RNAs. They negatively regulate (inhibit) gene expression either by inhibiting translation or cleaving messenger RNAs. Therefore, miRNAs are post-translational regulators that bind to complementary sequences of mRNA transcripts, pairing with the untranslated region (3'-UTR), generally resulting in translational repression or target degradation, resulting in gene silencing.
[0028] They are involved in the regulation of most molecular processes, and there is consistent scientific evidence of their relationship with various metabolic processes. Circulating miRNAs can be detected in the bloodstream, where they exhibit high stability and reproducibility. Circulating miRNAs can provide clinical information about pathophysiological conditions, enabling early diagnosis and the study of the progression of various diseases. Therefore, they are proposed as potential biomarkers.
[0029] Under a standard nomenclature system, experimentally confirmed miRNAs are named as follows: the prefix "mir", followed by a hyphen and a number. The uncapitalized "mir-" refers to the pre-miRNA, while an uppercase "m¡R-" refers to the mature form. miRNAs with nearly identical sequences (except for one or two nucleotides) are annotated with an additional lowercase letter, e.g., m¡R-99a. Pre-miRNAs that lead to 100% identical mature miRNAs but are located at different locations in the genome are indicated with an additional hyphen-number suffix. Species of origin may be designated with a three-letter prefix, with hsa being the one corresponding to a human (Homo sapiens) miRNA. In the context of this document, where all individualized miRNAs are human miRNAs, the "hsa-" prefix is sometimes omitted.When two mature miRNAs originate from opposite arms of the same pre-miRNA, they are denoted by a -3p or -5p suffix, such as m¡R-142-3p. When relative expression levels are known, an asterisk after the name indicates a miRNA expressed at low levels relative to the miRNA on the opposite arm of a hairpin. miRNA sequences can be accessed at http: / / www.mirbase.org.
[0030] BRIEF DESCRIPTION OF THE INVENTION
[0031] In the present invention, 6 miRNAs have been identified that act as biomarkers by being differentially expressed, both in lesional tissue and in peripheral blood, in patients with non-segmental vitiligo. Some of the deregulated miRNAs that make up this panel have been previously described in other dermatological diseases, but very few previous studies have analyzed the role of miRNAs in peripheral blood of patients with non-segmental vitiligo, and those that address this aspect yield contradictory results. Of the 6 miRNAs proposed in the panel of the invention, none have been previously described as associated with non-segmental vitiligo.
[0032] The present invention proposes a panel of microRNAs (miRNAs) whose expression is deregulated both in tissue samples isolated from skin lesions caused by vitiligo and in the plasma of patients with non-segmental vitiligo compared to healthy individuals, as biomarkers of the disease. Differences in the expression of this group of miRNAs result in deregulation of several immunological and metabolic pathways related to disease severity.
[0033] The 6 miRNAs that make up the panel of the invention for the diagnosis and prognosis of non-segmental vitiligo, or miRNAs of the invention, are the following: m¡R-16-5p, m¡R-92a-3p, m¡R-486-5p, m¡R-221-3p, m¡R-23a-3p and m¡R-652-3p.
[0034] All of them are differentially expressed in the lesional skin and plasma of patients with non-segmental vitiligo compared to controls, in whom no significant modifications were found.
[0035] The expression levels of the miRNAs of the invention are determined using samples of lesional skin or blood previously obtained from the patients. Therefore, a predictive model based on the determination of the expression levels of 6 miRNAs in lesional skin or plasma is proposed below. This disease classification method has the advantage of being objective and reproducible compared to current scales based on images or photographs.
[0036] In turn, by measuring the expression levels of the miRNAs of the invention over time, this method is capable of monitoring the therapeutic response to treatment of the disease with various drugs, said treatment.
[0037] Therefore, the method of the invention can also be used as a molecular predictor of therapeutic response to different treatments for non-segmental vitiligo. Thanks to the miRNAs proposed in the present invention and their differential expression in patients with non-segmental vitiligo, it is possible to carry out an assessment and repositioning of drugs capable of reversing this state of dysregulation. This assessment is carried out using the Cmaps and LINCS tools. The Broad Institute's Connectivity Map (CMap) project uses the library of integrated network-based cellular signatures (LINCS) and allows the generation of functional hypotheses from cellular signatures that represent systematic perturbations with genetic perturbagens (reflecting the function of proteins) and pharmacological perturbagens (reflecting the function of small molecules).
[0038] Once the lists of potential drugs marketed or in development, or molecules in the experimental phase contained in these databases were obtained, and after this analysis, 121 drugs were ultimately selected that were potentially capable of reversing the dysregulated state in the expression of the miRNAs of the invention. This is possible using GeneCodis, which uses the molecular signatures found to find similarities with other signatures produced by these perturbagens of interest and stored in the aforementioned databases. Finally, those results obtained with an FDR value < 0.05 and by relative enrichment value in descending order were selected.
[0039] Of this final list, 37.2% of the drugs that showed a potential capacity to reverse the profiles of gene dysregulation by miRNAs in non-segmental vitiligo were kinase inhibitors [headed by PI3K inhibitors (12.4%; alpelisib, pictilisib, PI-103, dactolisib, LY-294002, AS-605240, AZD-6482, ZSTK-474, TG100-115, PIK-75, KU-0060648, wortmannin, rigosertib, GSK-1059615, AS-604850); multi-kinases (dovitinib, sorafenib, tivozanib, sunitinib, pazopanib, regorafenib, imatinib, dasatinib, ENMD-2076, GTP- 14564, talazoparib, nilotinib, masitinib); IKK (BMS-345541, TPCA-1 , I KK-2 inhibitor-V, IKK- 16); JAK2 (fedratinib); VEGF (SU1498, cemaxanib, brivanib, Oxindole-I); VEGFR2 (cediranib, linifanib); HER / Erb2 (neratinib, CP-724714, tyrphostin-AG-825); PCK (bisindolylmaleimide-ix, SA-792987, 4,5,6,7-tetrabromobenzotriazole); Ras (manumycin); Rough (HG-6-64-01, GW-5074); p38 MAPK (SB-239063, SB-202190, adezmapimod); checkpoint kinase (SB-218078, AZD-7762); mTor kinase (everolimus, temsirolimus); MEK-1 (PD-98059, U-0126), FLT3 (tandutinib, midostaurin, quizartinib); CDK4 and CDK6 (abemaciclib, palbociclib, ribociclib); CDK9 (alvocidib)].
[0040] Other drugs identified were phosphodiesterase inhibitors (2.48%; cilomilast, sildenafil, YM-976), BCL-2 inhibitors (5.8%; ABT-737, navitoclax, TW-37, BH3I-1, HA-14-1, obatoclax, venetoclax), microtubule inhibitors (0.76%; eribulin, ixabepilone), survivin inhibitors (0.38%; YM-155), sirtuin inhibitors (0.38%; splitomycin), monoclonal antibodies [anti-VEGF (2.48%; aflibercept, ranibizumab, bevacizumab), anti-EGFR (1.65%; panitumumab, cetuximab), anti-HER2 (1.65%; pertuzumab, trastuzumab) and anti-TNF (0.83%; adalimumab)], antioxidants (8.26%; embelin, epigallocatechin, piceatannol, gossypol, edaravone, resveratrol, guggulsterone, curcumin, isoliquiritigenin, pentoxifylline), anti-inflammatories (9.09%; dapsone, flufenamic-acid, aspirin, celecoxib, ibuprofen, dexamethasone, mesalazine, sulfasalazine, corticosteroids), antimicrobials (3.31%; mepacrine, pyrimethamine, triclabendazole, triclosan), hormonal regulators (3.31%; danazol, levonorgestrel, gestrinone, tibolone), epigenetic modifiers (1.65%; zebularine, decitabine), p53 expression restorers (2.48%; pifithrin-alpha, prima-1-met, pifithrin-mu), PPARG receptor agonists (7.7%; troglitazone) and proteasome inhibitors (0.38%; carfilzomib).
[0041] Of these, 13.07% were substances with toxic effects, such as chemotherapy drugs, or substances that were in very early stages of development, so they were not considered a priority.
[0042] Therefore, the present invention also develops a method capable of predicting the therapeutic response of different treatments, whether in development or already approved for clinical use, against severe non-segmental vitiligo.
[0043] Finally, the present invention describes a kit for the analysis by RT-PCR of the 6 human miRNAs using samples of injured skin with the aim of identifying patients with vitiligo.
[0044] DETAILED DESCRIPTION OF THE INVENTION
[0045] A first aspect of the invention relates to the in vitro use of the expression levels of one or more of the following miRNAs: m¡R-16-5p, m¡R-92a-3p, m¡R-486-5p, m¡R-221-3p, m¡R-23a-3p and / or m¡R-652-3p as biomarkers for prognosing and / or diagnosing non-segmental vitiligo. In a preferred embodiment, the use of the expression levels of these biomarkers is simultaneous.
[0046] Table 1: miRNA sequences of the invention.
[0047] Another aspect of the invention relates to an expression profile of the miRNAs in Table 1, either individually or in any of their combinations, suitable for diagnosing non-segmental vitiligo, hereinafter referred to as the expression profile of biomarkers of the invention. Preferably, the expression profile comprises all the miRNAs in Table 1 simultaneously.
[0048] METHODS OF THE INVENTION
[0049] Another aspect of the invention relates to an in vitro method for obtaining data useful for diagnosing and / or prognosing severe non-segmental vitiligo, which comprises measuring the expression levels of one or more of the miRNAs listed in Table 1 in a previously isolated biological sample. Preferably, the expression levels of all the miRNAs listed in Table 1 are measured simultaneously.
[0050] In a preferred embodiment of this aspect of the invention, the biological sample is selected from injured skin or whole blood, serum or plasma, preferably plasma.
[0051] Another aspect of the present invention relates to an in vitro method for diagnosing and / or prognosing severe non-segmental vitiligo comprising: a) measuring the expression levels of one or more of the miRNAs in Table 1 in a previously isolated sample of lesional skin tissue, b) comparing the values obtained with those of a reference sample obtained from healthy control individuals, and c) classifying the individual in the group of individuals suffering from non-segmental vitiligo when the miRNA(s) from step a) are differentially expressed to a lower level compared to the samples from healthy control individuals.
[0052] Preferably, in step a) the expression levels of all miRNAs in Table 1 are measured simultaneously.
[0053] Another aspect of the present invention relates to an in vitro method for diagnosing and / or prognosing non-segmental vitiligo comprising: a) measuring the expression levels of all the miRNAs in Table 1 in a previously isolated blood, serum or plasma sample, b) comparing the values obtained with those of a reference sample obtained from healthy control individuals, and c) classifying the individual into the group of individuals suffering from severe non-segmental vitiligo when the miRNAs from step a) hsa.miR.16.5p, hsa.miR.486.5p and hsa.miR.92a.3p are differentially under-expressed and hsa.miR.652.3p, hsa.miR.221.3p, hsa.miR.23a.3p are differentially over-expressed with respect to the samples from healthy control individuals.
[0054] In vitro determination of expression levels is performed using any of the techniques known in the state of the art. Preferably, the techniques are selected from the list consisting of a gene profiling method, such as a microarray, or a next-generation sequencing panel; and / or a method comprising PCR, such as real-time PCR or RT-PCR; and / or Northern blotting; and / or an immunohistochemical method; and / or an ELISA-based method.
[0055] A microarray is an array on a solid substrate (usually a glass slide or a silicon thin film cell) that analyzes large amounts of biological material, in the present case a large number of different miRNAs or, preferably, their reverse DNA transcripts, which are detectable by specific probes immobilized on the solid substrate.
[0056] A Northern blot involves the use of electrophoresis to separate RNA samples by size and subsequent detection with a hybridization probe complementary to (part of) the RNA target sequence of interest.
[0057] The quantification of miRNA expression is preferably performed by RT-PCR. Reverse transcription PCR, or RT-PCR, allows the detection and amplification of RNA. RNA is reverse transcribed into complementary DNA (cDNA) using reverse transcriptase. The first step in RT-PCR is the synthesis of a DNA / RNA hybrid. Reverse transcriptase also has an RNase H function, which degrades the RNA portion of the hybrid. The single-stranded DNA molecule is then completed into cDNA by the reverse transcriptase activity of DNA-dependent DNA polymerase. From here, the standard PCR procedure is used to amplify the cDNA. The ability to reverse RNA into cDNA using RT-PCR has many advantages, as RNA is single-stranded and very unstable, making it difficult to work with.
[0058] The method of the present invention can be applied with samples from individuals of either sex, that is, men or women, and at any age.
[0059] In the method of the present invention, miRNA expression can be normalized, preferably relative to the expression of another RNA molecule. Normalization methods are well known in the art.
[0060] The invention provides a method for assigning a human subject into one of two groups: group 1, comprising subjects identifiable by the method of the invention, and group 2, representing the remaining subjects.
[0061] It is possible to provide personalized treatment to an individual depending on whether the individual is assigned to group 1 or group 2. Group 1 comprises subjects identifiable by the method of the invention as individuals suffering from non-segmental vitiligo and group 2 represents the remaining subjects.
[0062] In another embodiment of the method of the invention, it is capable of predicting the therapeutic response of different treatments against non-segmental vitiligo, whether in development or already approved for clinical use, based on their ability to reverse the state of dysregulation of the expression of the miRNAs of the invention.
[0063] Therefore, we are talking about the use of one or more miRNAs from Table 1, and preferably all of them simultaneously, in a method to predict the therapeutic response of different treatments for non-segmental vitiligo.
[0064] In this sense, another embodiment of the method of the invention relates to the method for predicting the therapeutic response of a patient with non-segmental vitiligo to a treatment against non-segmental vitiligo comprising: a) measuring the expression levels of one or more of the miRNAs in Table 1 in a biological sample previously isolated from a patient with non-segmental vitiligo prior to the administration of the treatment against vitiligo, b) measuring the expression levels of the same miRNAs from step a) in a biological sample previously isolated from the same patient with non-segmental vitiligo after administration of the treatment against vitiligo, c) comparing the values obtained in steps a) and b) and d) classifying the individual in the group of individuals responding to the treatment when the miRNA(s) from step b) are differentially expressed with respect to the samples from step a).
[0065] And on the other hand, it also refers to the method for predicting the therapeutic response of a treatment against non-segmental vitiligo in patients with non-segmental vitiligo comprising: a) measuring the expression levels of one or more of the miRNAs in Table 1 in biological samples previously isolated from a number of patients with statistically significant non-segmental vitiligo prior to the administration of the treatment against vitiligo, b) measuring the expression levels of the same miRNAs from step a) in a biological sample previously isolated from the same patients with non-segmental vitiligo after administration of the treatment against vitiligo, c) comparing the values obtained in steps a) and b),and d) classify the treatment against non-segmental vitiligo as effective when the miRNA(s) from step b) are differentially expressed with respect to the samples from step a) in a statistically significant number of patients with non-segmental vitiligo undergoing treatment.
[0066] Preferably, in both methods, in both steps a) and b), the expression levels of all miRNAs in Table 1 are measured simultaneously.
[0067] Among the potential drugs susceptible to being subjected to this assessment of therapeutic response, and therefore their suitability for the treatment of non-segmental vitiligo, kinase inhibitors stand out. KIT OR DEVICE OF THE INVENTION
[0068] Another aspect of the invention relates to a kit or device comprising at least one or more oligonucleotides capable of hybridizing to one or more of the miRNAs in Table 1 under stringent conditions. Preferably, it comprises at least one or more oligonucleotides capable of hybridizing to all of the miRNAs in Table 1 simultaneously under stringent conditions.
[0069] It is preferred that said oligonucleotide(s) be capable of doing so under stringency conditions. In a preferred embodiment, one or more of said one or more oligonucleotides (preferably DNA) are further defined by the following probes or primers: hsa-m¡RXX-m¡RCURY LNA miRNA measured with syber, LNA™ PCR specific primers.
[0070] Stringency is a term used in hybridization experiments. Stringency reflects the degree of complementarity between the oligonucleotide and the nucleic acid (which in this case is the miRNA to be detected); the higher the stringency, the higher the percentage of homology between the probe and the nucleic acid bound to the filter. Those skilled in the art are well aware that temperature and salt concentrations have a direct effect on the results obtained. It is recognized that hybridization results are related to the number of degrees below the Tm (melting temperature) of the DNA in which the experiment is performed. Stringent conditions are often defined as a wash with 0.1X SSC (saline-sodium citrate (SSC) buffer at 65 °C. (SSC is usually provided as a 20X stock solution, consisting of 3 M sodium chloride and 300 mM trisodium citrate (adjusted to pH 7.0 with HCl)).
[0071] In particular embodiments, the kit is selected from (a) a kit suitable for microarray analysis, (b) a kit suitable for PCR, (c) a kit suitable for Northern blotting, (d) a kit suitable for immunoassay. Two or more of these embodiments may also be combined, such that the kit may comprise, for example, both (a) and (c).
[0072] It is also possible for the oligonucleotide(s) to be immobilized on spots on a (preferably solid) surface. In one embodiment thereof, the kit comprises a microarray. An RNA microarray is an array on a solid substrate (usually a glass slide or a silicon thin film cell) that analyzes large quantities of different RNAs (in this case miRNAs), which can be detected by specific probes immobilized on spots of the solid substrate. Each spot contains a specific nucleic acid sequence, typically a DNA sequence, known as probes (or reporters). While the number of spots is not limited, there is a preferred embodiment wherein the microarray is adapted to the methods of the invention. In one embodiment, such a custom microarray comprises fifty spots or fewer, such as thirty spots or fewer, including twenty spots or fewer.
[0073] In the case of (b) a kit suitable for PCR, this PCR is typically a real-time quantitative PCR (RQ-PCR), a sensitive and reproducible gene expression quantification technique. In this case, it is desired that the kit additionally comprises a polyT oligonucleotide primer in addition to the oligonucleotide(s) of the kit. The polyT oligonucleotide primer can be used together with the oligonucleotide(s) of the invention for priming PCR, after polyadenylation of the isolated miRNAs by methods known to those skilled in the art, such as the use of poly-(A) polymerase and ATP. These reagents may optionally be included in the kit.
[0074] A Northern blot involves the use of electrophoresis to separate RNA samples by size and subsequent detection with an oligonucleotide(s) (hybridization probe) complementary to (part of) the RNA target sequence of interest.
[0075] The kit or device of the invention may be used and the use is not particularly limited, although use in the method of the invention in any of its embodiments is preferred.
[0076] In another preferred embodiment of this aspect of the invention, the oligonucleotides, primers, probes, or antibodies are modified or labeled, for example, but not limited to, by radioactive or immunological labeling. Thus, the oligonucleotides preferably have modifications in some of their nucleotides, such as, but not limited to, nucleotides that have one of their atoms with a radioactive isotope, typically 32P or tritium, immunologically labeled nucleotides, such as with a digoxigenin molecule, and / or immobilized on a membrane. Various possibilities are known in the state of the art.
[0077] The kit or device of the invention may comprise controls, program instructions and information necessary to carry out any of the methods of the invention.
[0078] Another aspect of the invention relates to the use of the kit according to any of the embodiments described above to carry out any of the embodiments of the method of the invention.
[0079] COMPUTER-IMPLEMENTED INVENTION Another aspect of the invention relates to computer-readable storage media comprising program instructions capable of causing a computer to perform the steps of any of the methods of the invention. The invention also extends to computer programs adapted to enable any processing means to carry out the methods of the invention. Such programs may take the form of source code, object code, an intermediate source of code and object code, for example, in partially compiled form, or in any other form suitable for use in implementing the processes according to the invention. Computer programs also encompass cloud applications based on this method. In particular, the invention encompasses computer programs arranged on or within a medium. The carrier may be any entity or device capable of supporting the program.When the program is embodied in a signal that can be transported directly by a cable or other device or medium, the carrier may be constituted by said cable or other device or medium. As a variable, the carrier could be an integrated circuit on which the program is included, the integrated circuit being adapted to execute, or to be used in the execution of, the corresponding processes.
[0080] For example, the programs could be embedded in a storage medium, such as a ROM, a CD-ROM, or a semiconductor ROM, a USB memory stick, or a magnetic recording medium, e.g., a floppy disk or a hard disk. Alternatively, the programs could be supported by a transmissible carrier signal. For example, it could be an electrical or optical signal that could be transported through an electrical or optical cable, by radio, or by any other means. The invention also extends to computer programs adapted to allow any processing medium to carry out the methods of the invention. Such programs may take the form of source code, object code, intermediate source code, and object code, e.g., in partially compiled form, or in any other form suitable for use in implementing the processes according to the invention.Computer programs also encompass cloud applications based on this method. Therefore, another aspect of the invention relates to a computer-readable storage medium comprising program instructions capable of causing a computer to perform the steps of any of the methods of the invention.
[0081] Another aspect of the invention relates to a transmissible signal comprising program instructions capable of causing a computer to carry out the steps of any of the methods of the invention. In the context of the present invention, the terms "subject," "patient," or "individual" are used interchangeably herein to refer to all animals classified as mammals and include, but are not limited to, domestic and farm animals, primates, and humans, for example, humans, non-human primates, cows, horses, pigs, sheep, goats, dogs, cats, or rodents. Preferably, the subject is a male or female human of any age or race.
[0082] Throughout the description and claims, the word "comprises" and its variants are not intended to exclude other technical features, accessories, components, or steps. For those skilled in the art, other objects, advantages, and features of the invention will be understood in part from the description and in part from the practice of the invention. The following examples and drawings are provided for illustrative purposes and are not intended to limit the present invention.
[0083] An "isolated biological sample" includes, but is not limited to, cells, tissues, and / or biological fluids from an organism, obtained by any method known to a person skilled in the art. Preferably, the isolated biological sample is skin or peripheral venous blood.
[0084] The terms “one or more” or “at least one” or “several,” as used herein, include one and the individualized specification of any number that is more than one, such as two, three, four, five, six, etc.
[0085] EXAMPLES OF THE INVENTION
[0086] The present invention is based on the analysis of 740 miRNAs in samples of lesional skin and peripheral blood from patients with non-segmental vitiligo (n=20) and healthy controls (n=10).
[0087] Following protocol approval by the local Research Ethics Committee, patients were selected based on the following criteria: a) adults; b) with clinically or histologically diagnosed non-segmental vitiligo; c) naive to local, systemic treatments or after drug washout (2 weeks for topical treatments and 4 weeks for non-biological systemic treatments); d) without other comorbidities or autoimmune disease, except for Hashimoto's thyroiditis in a euthyroid state.
[0088] Vitiligo severity was assessed using the VASI scale, and disease progression was calculated based on each patient's clinical history. Once consent was obtained from the patient, photographs were taken, and skin biopsies were obtained under local anesthesia with a 5-mm punch from lesional areas (LE) and nonlesional areas (NL). A single skin sample was obtained from healthy controls. Peripheral venous blood samples were obtained from all participants.
[0089] These samples were analyzed by RT-PCR using the OpenArray system and Thermofisher Connect. Expression values [threshold cycle (Ct)] were normalized with miRNA expression values by negative transformation of Ct values to -dCt. Missing values were estimated for each gene as 20% of the minimum expression values in all samples. After performing quality control and batch correction, expression differences between groups were analyzed using a non-parametric approach using the Wilcoxon test and considering a significance level of p <0.05. In this way, different ordered lists of differentially expressed miRNAs were obtained.
[0090] Statistical analyses were performed using the R statistical language (www.r-project.org).
[0091] As a result, 90 miRNAs were identified in lesional skin that were differentially expressed in patients with non-segmental vitiligo compared to healthy volunteers, in whom no significant modifications were found (p<0.05). These miRNAs are identified in Table 2, indicating the level of expression in patients with non-segmental vitiligo and in controls, as well as the associated p values for each case.
[0092] Table 2. List of miRNAs with significantly different expression in lesional skin samples from patients with non-segmental vitiligo vs controls.
[0093] Fold miRNAs vitiligo controls P value
[0094] Change hsa.m¡R.365a.3p 0.4188956 1.1509775 0.0060848554701539 -0.7320819 hsa.m¡R.1249.3p 0.3469913 0.9169925 0.00790001969082206 -0.5700012 hsa.m¡R.664a.3p 0.4534453 1.1509775 0.00790001969082206 -0.6975322 hsa.m¡R.92a.3p 0.4797487 1.1509775 0.0095124048725034 -0.6712288 hsa.m¡R.106b.5p 0.4234893 1.033985 0.00985696008583745 -0.6104957 hsa.m¡R.149.5p 0.4493481 1.1509775 0.00985696008583745 -0.7016294 hsa.m¡R.374a.5p 0.4299988 1.033985 0.00985696008583745 -0.6039862 hsa.m¡R.374b.5p 0.4256919 1.033985 0.00985696008583745 -0.6082931 hsa.m¡R.425.5p 0.4234893 1.033985 0.00985696008583745 -0.6104957 hsa.m¡R.148a.3p 0.4486787 1.1509775 0.00992659306922461 -0.7022988 hsa.m¡R.26a.5p 0.4519953 1.1509775 0.00992659306922461 -0.6989822 hsa.m¡R.203a.3p 0.4345924 1.1509775 0.0100665773973097 -0.7163851 hsa.m¡R.200c.3p 0.6001628 1.1509775 0.0101466589313789 -0.5508147 hsa.m¡R.99a.5p 0.4700526 1.1509775 0.0109464598439017 -0.6809249 hsa.m¡R.224.5p 0.4797487 1.033985 0.0110234163882214 -0.5542363 hsa.m¡R.193b.3p 0.5323556 1.1509775 0.0113233290719574 -0.6186219 hsa.m¡R.296.5p 0.4563022 1.033985 0.0114905238785233 -0.5776828 hsa.m¡R.30b.5p 0.4497927 1.033985 0.0114905238785233 -0.5841923 hsa.m¡R.93.5p 0.4334783 1.033985 0.0116482577894378 -0.6005067 hsa.m¡R.1271 ,5p 0.5212525 1.033985 0.0119050810662381 -0.5127325 hsa.m¡R.148b.3p 0.5630985 1 0.0119050810662381 -0.4369015 hsa.m¡R.423.3p 0.5212525 1.033985 0.0119050810662381 -0.5127325 hsa.m¡R.455.3p 0.5212525 1.033985 0.0119050810662381 -0.5127325 hsa.m¡R.130a.3p 0.4760962 1.033985 0.0126729439685062 -0.5578888 hsa.m¡R.205.5p 0.4608958 1.033985 0.0126729439685062 -0.5730892 hsa.m¡R.30c.5p 0.4782988 1.033985 0.0126729439685062 -0.5556862 hsa.m¡R.29c.5p 0.5198025 1.033985 0.0131344295302774 -0.5141825 hsa.m¡R.324.5p 0.5198025 1.033985 0.0131344295302774 -0.5141825 hsa.m¡R.195.3p 0.4510885 0.9509775 0.0136013995262562 -0.499889 hsa.m¡R.486.5p 0.3750869 1.1323556 0.0139107724904636 -0.7572687 hsa.m¡R.106b.3p 0.4908519 0.9169925 0.0140756679761432 -0.4261406 Fold miRNAs vitiligo controls P value.
[0095] Change hsa.miR.378a.3p 0.4686456 1.033985 0.0141713882540123 -0.5653394 hsa.miR.194.5p 0.2803896 1.0153631 0.0144570241220671 -0.7349735 hsa.miR.494.3p 0.4241674 1.1509775 0.0152936533065191 -0.7268101 hsa.miR.429 0.3445789 1.0153631 0.0162248212813898 -0.6707842 hsa.miR.204.5p 0.3856381 1.0983706 0.0162752337441366 -0.7127325 hsa.miR.199b.5p 0.471784 1.033985 0.0204432159782943 -0.562201 hsa.miR.192.5p 0.4732947 1.033985 0.0210350160709514 -0.5606903 hsa.miR.34a.5p 0.5591037 1.1509775 0.0212610876077463 -0.5918738 hsa.miR.29b.3p 0.5497927 1.1509775 0.0216410138445844 -0.6011848 hsa.let.7b.3p 0.6586591 1.1509775 0.0218556343405187 -0.4923184 hsa.miR.28.3p 0.6416666 1.1509775 0.022320268763123 -0.5093109 hsa.miR.151a.5p 0.6060522 1.1509775 0.022626299499965 -0.5449253 hsa.miR.25.3p 0.6060522 1.1509775 0.022626299499965 -0.5449253 hsa.miR.140.3p 0.538245 1.033985 0.0227957869735389 -0.49574 hsa.miR.154.5p 0.5299988 1.033985 0.0227957869735389 -0.5039862 hsa.miR.93.3p 0.5826057 1.1509775 0.0230376672528961 -0.5683718 hsa.miR.26b.5p 0.4782988 1.1849625 0.0231753899516528 -0.7066637 hsa.miR.99b.3p 0.5230447 1.033985 0.0234468127750727 -0.5109403 hsa.miR.29c.3p 0.508289 1.033985 0.0235778133995956 -0.525696 hsa.miR.191 ,5p 0.5797487 1.033985 0.0247096888099684 -0.4542363 hsa.miR.24.3p 0.5797487 1.033985 0.0247096888099684 -0.4542363 hsa.miR.532.3p 0.5797487 1.033985 0.0247096888099684 -0.4542363 hsa.miR.361 ,5p 0.3934996 1.0983706 0.0249020630565251 -0.704871 hsa.miR.16.5p 0.3971858 0.9813781 0.0252761920464 -0.5841923 hsa.miR.629.5p 0.4645484 0.9509775 0.0255611128335053 -0.4864291 hsa.miR.484 0.5493481 1.033985 0.0258471320626969 -0.4846369 hsa.miR.345.5p 0.536795 1.033985 0.0259905502476329 -0.49719 hsa.miR.125a.5p 0.6586591 1.033985 0.0261897379012848 -0.3753259 hsa.miR.1301 ,3p 0.6060522 1.033985 0.0267908008556994 -0.4279328 hsa.let.7e.3p 0.5826057 1.033985 0.0272531967766466 -0.4513793 hsa.miR.126.3p 0.5756516 1.033985 0.0272531967766466 -0.4583334 hsa.miR.151 b 0.5908519 1.033985 0.0272531967766466 -0.4431331 hsa.miR.218.5p 0.5908519 1.033985 0.0272531967766466 -0.4431331 Fold miRNAs vitiligo controls P value.
[0096] Change hsa.miR.326 0.5756516 1.033985 0.0272531967766466 -0.4583334 hsa.m¡R.151a.3p 0.6323556 1.033985 0.0273949730896586 -0.4016294 hsa.m¡R.328.3p 0.5674053 1.033985 0.0274079127034367 -0.4665797 hsa.m¡R.125b.5p 0.6171553 1.033985 0.0275594988114761 -0.4168297 hsa.m¡R.221 ,3p 0.6171553 1.033985 0.0275594988114761 -0.4168297 hsa.m¡R.497.5p 0.5871993 1.033985 0.0275594988114761 -0.4467857 hsa.m¡R.17.5p 0.3808715 1.1323556 0.0277322967875613 -0.7514841 hsa.m¡R.23a.3p 0.6153631 1.033985 0.0295585835294018 -0.4186219 hsa.m¡R.758.3p 0.6153631 1.033985 0.0295585835294018 -0.4186219 hsa.m¡R.199a.5p 0.5334783 0.9169925 0.0297625165405284 -0.3835142 hsa.m¡R.425.3p 0.6230447 1.033985 0.0305609631681744 -0.4109403 hsa.m¡R.128.3p 0.5604513 0.9169925 0.0307450347589932 -0.3565412 hsa.m¡R.10b.5p 0.594949 1.150978 0.0310431524724214 -0.556029 hsa.m¡R.214.3p 0.5894019 0.9169925 0.0317010306854173 -0.3275906 hsa.m¡R.20a.5p 0.3803112 1.0153631 0.0328304964085471 -0.6350519 hsa.m¡R.335.5p 0.5256919 1.06797 0.0343873103418464 -0.5422781 hsa.m¡R.15a.5p 0.60281 1.150978 0.0356271004877229 -0.548168 hsa.m¡R.1296.5p 0.5212525 1.06797 0.0368788018411012 -0.5467175 hsa.m¡R.29b.2.5p 0.5749821 1.1509775 0.0379607574725193 -0.5759954 hsa.m¡R.378a.5p 0.538245 1.033985 0.0385047628410804 -0.49574 hsa.m¡R.34a.3p 0.506193 1.033985 0.0395986235887438 -0.527792 hsa.m¡R.195.5p 0.4782988 0.9813781 0.0431832773036339 -0.5030793 hsa.m¡R.99a.3p 0.6586591 1.1509775 0.0436835892303467 -0.4923184 hsa.m¡R.652.3p 0.5738594 1.0983706 0.0439104994182379 -0.5245112 hsa.m¡R.188.5p 0.5212525 1.0983706 0.04775347478001 -0.5771181 hsa.m¡R.221 ,5p 0.597806 1.033985 0.0499242840396976 -0.436179.
[0097] A series of miRNAs were also identified that were differentially expressed in plasma samples from patients with non-segmental vitiligo compared to controls. The results are shown below Table 3 and correspond to the following miRNAs: m¡R-16-5p, m¡R-92a-3p, m¡R-486-5p, m¡R-221-3p, m¡R-23a-3p and miR-652-3p. Table 3. List of miRNAs with significantly different expression in plasma samples from patients with non-segmental vitiligo vs controls.
[0098] It was found that the 6 miRNAs dysregulated in plasma in patients with non-segmental vitiligo were also found in the panel of miRNAs underexpressed in lesional skin in Table 1, thus confirming that the miRNA panel of the invention is selective to represent the degree of systemic affectation of patients with vitiligo.
[0099] References 1. Montilla AM, Gomez-Garcia F, Gomez-Arias PJ, Gay-Mimbrera J, Hernandez-Stop J, Island-Tejera B, Ruano J. Dermatol Ther (Heidelb),
[0100] 2. Zhang L, Chen S, Kang Y, Wang X, Yan F, Jiang M, Wang Q, Liu Z, Zhang C, Xiang L. Association of Clinical Markers With Disease Progression in Patients With Vitiligo From China. JAMA Dermatol. 2020 Mar 1;156(3):288-295. doi: 10.1001 / jamadermatol.2019.4483.
[0101] PMID: 31968061; PMCID: PMC6990655.
Claims
MODIFIED CLAIMS received by the International Bureau on 5 November 2024 (05.11.2024) 1. In vitro use of the expression levels of the miRNAs in Table 1 simultaneously as biomarkers to diagnose and / or prognose non-segmental vitiligo.
2. An in vitro method for obtaining data useful for diagnosing and / or prognosing non-segmental vitiligo comprising measuring the expression levels of all the miRNAs in Table 1 in a biological sample of lesional skin tissue or previously isolated blood, serum or plasma.
3. An in vitro method for diagnosing and / or prognosing non-segmental vitiligo comprising: a) measuring the expression levels of all the miRNAs in Table 1 in a previously isolated sample of lesional skin tissue, b) comparing the values obtained with those of a reference sample obtained from healthy control individuals, and c) classifying the individual into the group of individuals suffering from severe non-segmental vitiligo when the miRNAs from step a) are differentially expressed to a lower level compared to the reference sample of healthy control individuals.
4. An in vitro method for diagnosing and / or prognosing non-segmental vitiligo comprising: a) measuring the expression levels of all the miRNAs in Table 1 in a previously isolated blood, serum or plasma sample, b) comparing the values obtained with those of a reference sample obtained from healthy control individuals, and c) classifying the individual into the group of individuals suffering from severe non-segmental vitiligo when the miRNAs from step a) hsa.miR.16.5p, hsa.miR.486.5p and hsa.miR.92a.3p are differentially expressed downwards and hsa.miR.652.3p, hsa.miR.221.3p, hsa.miR.23a.3p are differentially expressed upwards with respect to the reference samples from healthy control individuals.
5. Use of the miRNAs in Table 1 in a method to predict the therapeutic response of a treatment against non-segmental vitiligo.
6. Method for predicting the therapeutic response of a patient with non-segmental vitiligo to a treatment against non-segmental vitiligo comprising: a) measuring the expression levels of all the miRNAs in Table 1 in a biological sample previously isolated from a patient with non-segmental vitiligo prior to the administration of the treatment against vitiligo, b) measuring the expression levels of the same miRNAs from step a) in a biological sample previously isolated from the same patient with non-segmental vitiligo after administration of the treatment against vitiligo, c) comparing the values obtained in steps a) and b), and d) classifying the individual in the group of individuals responding to the treatment when the miRNAs from step b) are differentially expressed with respect to the samples from step a).
7. Method for predicting the therapeutic response of a treatment against non-segmental vitiligo in patients with non-segmental vitiligo comprising: a) measuring the expression levels of all the miRNAs in Table 1 in biological samples previously isolated from a statistically significant number of patients with non-segmental vitiligo prior to administration of the treatment against vitiligo, b) measuring the expression levels of the same miRNAs from step a) in a biological sample previously isolated from the same patients with non-segmental vitiligo after administration of the treatment against vitiligo, c) comparing the values obtained in steps a) and b), and d) classifying the treatment against non-segmental vitiligo as effective when the miRNAs from step b) are differentially expressed with respect to the samples from step a) in a statistically significant number of patients with non-segmental vitiligo undergoing the treatment.
8. The method according to any of claims 6 to 7, characterized in that the previously isolated biological sample is selected from injured skin, blood, plasma and serum.
9. The method according to the preceding claim, characterized in that the previously isolated biological sample is injured skin tissue.
10. The method according to any one of claims 2 to 4 and 6 to 9, wherein said result can be obtained by: (i) a miRNA profiling method, such as a microarray, and / or (i) a method comprising PCR (polymerase chain reaction), such as real-time PCR or RT-PCR and / or (iii) a Northern Blot and / or (iv) an immunoassay, such as an immunohistochemical method or an ELISA-based method.
11. A kit or device consisting of one or more oligonucleotides capable of hybridizing to all miRNAs in Table 1 simultaneously under stringent conditions.
12. Use of the kit according to the preceding claim in a method according to any of claims 2 - 4 and 6 to 10. Declaration under Article 19(1) The present modifications are provided in order to correct the lack of unity of invention detected during the international search and to overcome the objection to the novelty of claim 11 directed to the kit of the invention.
Citation Information
Patent Citations
Proteins of the WNT signaling pathway and uses thereof in the diagnostic and treatment of hypopigmentation disorders
WO2016097035A1
Mirna fingerprint in the diagnosis of lung cancer
WO2010139810A1
